Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma

Abstract Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in...

Full description

Bibliographic Details
Main Authors: Steven W. Yancey, Hector G. Ortega, Oliver N. Keene, Eric S. Bradford
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Adolescent
Asthma control
Eosinophils
Exacerbations
Mepolizumab
Severe eosinophilic asthma
Online Access:http://link.springer.com/article/10.1186/s13223-019-0366-x

Internet

http://link.springer.com/article/10.1186/s13223-019-0366-x

Similar Items